18 September 2020 : Original article
ABO-Incompatible Living Donor Liver Transplantation with Reduced Rituximab Dose: A Retrospective Analysis of 65 Patients – Can We Fast-Track Liver Transplant Surgery and Improve Long-Term Survival?
Shih-Chao Hsu123ABCDEF, Ashok Thorat13ABCEF, Long-Bin Jeng143ABCDEF*, Ping-Chun Li135ADF, Te-Hung Chen123BCF, Horng-Ren Yang123BDE, Kin-Shing Poon36DFDOI: 10.12659/AOT.923502
Ann Transplant 2020; 25:e923502
Table 1 General characteristics of study cohort.
| Variables | Era III ABOi LDLT recipients (n=50) |
|---|---|
| Male: Female | 38: 12 |
| Age (years) | 54±8 years (range, 32 to 67 years) |
| HCV related ESLD | 3 |
| HBV related ESLD | 5 |
| HCC | 27 |
| Others | 15 |
| MELD score | 16±8 (range, 6–41) |
| ABOi donation | |
| A to O | 20 |
| B to O | 15 |
| A to B | 2 |
| B to A | 2 |
| AB to A | 8 |
| AB to B | 3 |
| Rituximab dose | 200 mg single dose |
| LDLT performed within 5 days of rituximab | 7 |
| DFPP sessions | 4 |
| CD 19 B cell count | |
| Pre-rituximab | 16±10.8 (range, 2.1–54.2) |
| Pre-LDLT | 0.5 ± 1.0 (range, 0–6) |
| Post-LDLT | 0.7 ± 1.1 (range, 0–6.4) |
| Splenectomy | 1 |